Back to results
US 7,115,578 B2Granted
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
AssigneeSchering Corporation
InventorsAshit K. Ganguly, Jinping McCormick, Raymond G. Lovey, Frank Bennett, Anil K. Saksena, Viyyoor M. Girijavallabhan
Life of this patent
Estimating the term…
Abstract
Ribavirin derivatives represented by the formula V, pharmaceutical compositions containing them as well as the use of the ribavirin derivatives represented by the formula V for the preparation of a medicament for the treatment of susceptible viral infections, for example, chronic hepatitis C infections administrating, the ribavirin derivatives being represented by formula V are disclosed.
Claims7
A compound represented by formula V
- wherein R20CO— is a natural or unnatural amino acid moiety represented by the formulas
- Y═H, CH3;
- CH3CH2—;
- CH3CH2CH2—;
- Me2CH—;
- Me2CH2CH2—;
- CH3CH2CH(Me)—PhCH2—;
- HOOCCH2CH2—;
- HSCH2—;
- HOOCCH2—;
- MeSCH2CH2—;
- HOCH2—;
- or Y is H2N(CH2)4— or CH3CH(OH)—;
- or a pharmaceutically acceptable salt thereof;
- or Y taken together with the α carbon and N form
- or a phamaceutically acceptable salt thereof;
- or Y taken together with the α carbon and N form
- or a phamaceutically acceptable salt thereof,
- and wherein R21 is H, alkyl, alkanoyl, or aryl, or is alkyl, alkanoyl or aryl substituted by halo, phenyl, CN, NO2OH, CO2H or alkoxy.
16 more elements
Dependencies are inferred from the claim text.